Open Access Articles- Top Results for Dutasteride


Systematic (IUPAC) name
(5α, 17β)-N-{2,5-Bis(trifluoromethyl)phenyl}-3-oxo-4-azaandrost-1-ene-17-carboxamide
Clinical data
Trade names Avodart
AHFS/ monograph
MedlinePlus a603001
  • US: X (Contraindicated)
  • Not to be handled by pregnant women
Pharmacokinetic data
Bioavailability 60%
Protein binding 99%
Metabolism Hepatic (CYP3A4-mediated)
Half-life 5 weeks
Excretion Fecal
164656-23-9 7pxY
PubChem CID 6918296
DrugBank DB01126 7pxY
ChemSpider 5293502 7pxY
KEGG D03820 7pxY
ChEBI CHEBI:521033 7pxY
ChEMBL CHEMBL1200969 7pxN
Synonyms GG-745, GI-198745
Chemical data
Formula C27H30F6N2O2
528.53 g/mol
 14pxN (what is this?)  (verify)

Dutasteride (Avodart), manufactured by GlaxoSmithKline, is a dual 5-α reductase inhibitor that inhibits conversion of testosterone to dihydrotestosterone (DHT). It is used to treat benign prostatic hyperplasia. It increases the risk of erectile dysfunction[1] and decreased sexual desire.[2]

Medical uses

Avodart (dutasteride) 500 µg soft capsules

Dutasteride is useful for treating benign prostatic hyperplasia (BPH); colloquially known as an "enlarged prostate".[3]

In those who are being regularly screened, 5-alpha-reductase inhibitors such as finasteride and dutasteride reduce the overall risk of being diagnosed with prostate cancer; however, there is insufficient data to determine if they have an effect on the risk of death and may increase the chance of more serious cases.[4]

Adverse effects

Sexual effects

This class of medications increases rates of erectile dysfunction (with between 5% and 9% developing problems after starting their use).[1] This is linked to lower quality of life and can cause stress in relationships.[1] There is also an association with lowered sexual desire.[2] It has been reported that these adverse sexual side effects may persist even after discontinuation of the drug.[2]

Prostate cancer

The FDA has added a warning to dutasteride about an increased risk of high-grade prostate cancer.[5] While the potential for positive, negative or neutral changes to the potential risk of developing prostate cancer with dutasteride has not been established, evidence has suggested it may temporarily reduce the growth and prevalence of benign prostate tumors, but could also mask the early detection of prostate cancer. The primary area for concern is for patients who may develop prostate cancer whilst taking dutasteride for benign prostatic hyperplasia, which in turn could delay diagnosis and early treatment of the prostate cancer, thereby potentially increasing the risk of these patients developing high-grade prostate cancer.[6]


Children and women who are or may become pregnant, and people with known significant hypersensitivity (e.g., serious skin reactions, angioedema) to dutasteride or finasteride should not take dutasteride. Exposure to dutasteride and other 5-alpha reductase inhibitors during pregnancy can cause birth defects. Since these medications are readily absorbed through the skin, women who are or may become pregnant should not handle them and if they come into contact with leaking capsules, the contact area should be washed immediately in soapy water. People taking dutasteride should not donate blood and, due to its long half-life, should also not donate blood for at least 6 months after the cessation of treatment.[7]

Mechanism of action

Dutasteride belongs to a class of drugs called 5-alpha-reductase inhibitors, which block the action of the 5-alpha-reductase enzymes that convert testosterone into dihydrotestosterone (DHT).

Dutasteride versus finasteride

Finasteride is also approved for the treatment of benign prostatic hyperplasia, or BPH. The medications belong to the same class of drugs.

Dutasteride inhibits two of the three isoforms of 5-alpha reductase, I and II, whereas finasteride only inhibits type II, and has a much shorter half-life.

Bexlosteride is an isoform I selective inhibitor,[citation needed] albeit with limited commercial availability.

Society and culture

FDA approval

Dutasteride is approved by the Food and Drug Administration (FDA) for treatment of benign prostatic hyperplasia.


  1. ^ a b c Gur, S; Kadowitz, PJ; Hellstrom, WJ (January 2013). "Effects of 5-alpha reductase inhibitors on erectile function, sexual desire and ejaculation.". Expert opinion on drug safety 12 (1): 81–90. PMID 23173718. doi:10.1517/14740338.2013.742885. 
  2. ^ a b c Traish, AM; Hassani, J; Guay, AT; Zitzmann, M; Hansen, ML (March 2011). "Adverse side effects of 5α-reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients.". The journal of sexual medicine 8 (3): 872–84. PMID 21176115. doi:10.1111/j.1743-6109.2010.02157.x. 
  3. ^ Slater, S; Dumas, C; Bubley, G (March 2012). "Dutasteride for the treatment of prostate-related conditions.". Expert opinion on drug safety 11 (2): 325–30. PMID 22316171. doi:10.1517/14740338.2012.658040. 
  4. ^ Wilt TJ, MacDonald R, Hagerty K, Schellhammer P, Kramer BS (2008). "Five-alpha-reductase Inhibitors for prostate cancer prevention". Cochrane Database Syst Rev (2): CD007091. PMID 18425978. doi:10.1002/14651858.CD007091. 
  5. ^ 5-alpha reductase inhibitors (5-ARIs): Label Change - Increased Risk of Prostate Cancer | U.S. Department of Health & Human Services
  6. ^ Walsh, PC (Apr 1, 2010). "Chemoprevention of prostate cancer.". The New England Journal of Medicine 362 (13): 1237–8. PMID 20357287. doi:10.1056/NEJMe1001045. 
  7. ^ "FDA prescribing information" (PDF). June 2011. Retrieved 15 September 2013. 

External links